Some people with colorectal cancer have a genetic mutation causing them to have an MMR deficient/MSI-High tumor. Past research shows that treating MMR deficient/MSI-High colorectal cancer tumors can ...
Microsatellite instability (MSI), which results from defects in the DNA mismatch repair system, is an important biomarker in colorectal cancer. While the MSI-high (MSI-H) status predicts response to ...
A French prospective real-life cohort confirmed the favorable prognosis of nonmetastatic microsatellite instability (MSI) colorectal cancers. These cancers nevertheless entailed a high risk for ...
While immune checkpoint inhibitors (anti-PD-1 +/- anti-CTLA-4) are approved as first line treatment for microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), many patients ...
CHICAGO — Combination immunotherapy significantly improved outcomes vs. first-line chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer ...
WRN inhibitors are attracting increasing attention as a niche but fast-emerging segment within precision oncology, driven by their role in targeting DNA repair vulnerabilities. Promising candidates, ...
Initial Dose Adjustment of Zolbetuximab Plus Chemotherapy in CLDN18.2-Positive Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer (GENTLE-Z), a Randomized, Phase II Trial ...
The risk of disease progression or death was reduced by 79% with nivolumab/ipilimumab compared with chemotherapy. The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback